ARTICLE | Deals
NewAmsterdam preps for launch of well-traveled CETP inhibitor via Menarini deal
Deal for European rights shows Menarini’s continued appetite for adding innovative assets
June 29, 2022 12:10 AM UTC
With the potential for a European approval within the next three years, NewAmsterdam is starting to lay the groundwork for commercializing its CETP inhibitor through a partnership with Menarini that will also help to fund the ongoing Phase III studies.
On Tuesday, NewAmsterdam Pharma B.V. granted Menarini Group European rights to its late-stage dyslipidemia therapy obicetrapib. NewAmsterdam will receive €115 million ($121.8 million) up front and €27.5 million in R&D funding and is eligible for up to €863 million in clinical, regulatory and commercial milestones, plus double-digit royalties...